Clinical trial

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

NCT06902350

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-05-21

PhasePHASE1

Study timeline

Study start (actual)2025-05-21Date precision: day

Registry last updated2025-05-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Neoplasmsunresolved

Glioblastoma, Adultunresolved

Small Cell Lung Carcinoma (SCLC)unresolved

Interventions

CS231295DRUG

Sponsors & collaborators

Chipscreen Biosciences, Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China1 ChangchunJilin, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06902350 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.